Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2020 Filed Dec 1, 2020 23:11 UTC Amendment |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock Options · Derivative | 20,776 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-030246 · form4a.xml · derivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,776 Underlying: ResMed Common Stock · 20,776 shares Expires 2027-11-19 F1 · shares: Corrects original reported option grant for updated Black-Scholes valuation. F1 · derivative.underlying_shares: Corrects original reported option grant for updated Black-Scholes valuation. Read SEC document |
| November 19, 2020 Filed Dec 1, 2020 21:26 UTC Amendment |
Drexler KarenDirector
|
GrantResMed Common Stock Options · Derivative | 2,308 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-030208 · form4a.xml · derivative · entry 2 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,308 Underlying: ResMed Common Stock · 2,308 shares Expires 2027-11-19 F1 · shares: Corrects original reported option grant for updated Black-Scholes valuation. F1 · derivative.underlying_shares: Corrects original reported option grant for updated Black-Scholes valuation. Read SEC document |
| November 19, 2020 Filed Dec 1, 2020 21:26 UTC Amendment |
Drexler KarenDirector
|
GrantResMed Common Stock | 594 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030208 · form4a.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,981 Read SEC document |
| November 19, 2020 Filed Dec 1, 2020 21:24 UTC Amendment |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 7,849 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-030207 · form4a.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,849 Underlying: ResMed Common Stock · 7,849 shares Expires 2027-11-19 F1 · shares: Corrects original reported option grant for updated Black-Scholes valuation. F1 · derivative.underlying_shares: Corrects original reported option grant for updated Black-Scholes valuation. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 00:21 UTC |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 11,813 | $214.74 | $2,536,723.62 |
DisclosureSEC source: 0001127602-20-029626 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,199 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 00:20 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 26,246 | $214.74 | $5,636,066.04 |
DisclosureSEC source: 0001127602-20-029625 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,600 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. F2 · balance_after: Includes 78.73 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:50 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 10,249 | $214.74 | $2,200,870.26 |
DisclosureSEC source: 0001127602-20-029619 · form4.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,675 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:50 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 18,373 | $214.74 | $3,945,418.02 |
DisclosureSEC source: 0001127602-20-029619 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,924 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:48 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 49,776 | $214.74 | $10,688,898.24 |
DisclosureSEC source: 0001127602-20-029558 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,146 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:48 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 89,238 | $214.74 | $19,162,968.12 |
DisclosureSEC source: 0001127602-20-029558 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,922 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 12,445 | $214.74 | $2,672,439.30 |
DisclosureSEC source: 0001127602-20-029557 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,005 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 22,310 | $214.74 | $4,790,849.40 |
DisclosureSEC source: 0001127602-20-029557 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,450 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 18:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 34,958 | $214.74 | $7,506,880.92 |
DisclosureSEC source: 0001127602-20-029546 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,080 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 18:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 59,057 | $214.74 | $12,681,900.18 |
DisclosureSEC source: 0001127602-20-029546 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,038 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 18:51 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 15,547 | $214.74 | $3,338,562.78 |
DisclosureSEC source: 0001127602-20-029544 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,133 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 18:51 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 26,246 | $214.74 | $5,636,066.04 |
DisclosureSEC source: 0001127602-20-029544 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,680 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:10 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,211 | $212.11 | $256,865.21 |
DisclosureSEC source: 0001127602-20-029034 · form4.xml · nonDerivative · entry 3 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,551 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:10 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,418 | $212.11 | $300,771.98 |
DisclosureSEC source: 0001127602-20-029034 · form4.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,762 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:10 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 982 | $212.11 | $208,292.02 |
DisclosureSEC source: 0001127602-20-029034 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,180 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 72.85 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:06 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 2,221 | $212.11 | $471,096.31 |
DisclosureSEC source: 0001127602-20-029033 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,684 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:06 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 2,973 | $212.11 | $630,603.03 |
DisclosureSEC source: 0001127602-20-029033 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,905 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:06 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,417 | $212.11 | $724,779.87 |
DisclosureSEC source: 0001127602-20-029033 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,878 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 121.68 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:02 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 490 | $212.11 | $103,933.90 |
DisclosureSEC source: 0001127602-20-029032 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,140 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:02 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 722 | $212.11 | $153,143.42 |
DisclosureSEC source: 0001127602-20-029032 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,630 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:02 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 855 | $212.11 | $181,354.05 |
DisclosureSEC source: 0001127602-20-029032 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,352 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 78.84 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:01 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 579 | $212.11 | $122,811.69 |
DisclosureSEC source: 0001127602-20-029031 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,449 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:43 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 1,717 | $212.11 | $364,192.87 |
DisclosureSEC source: 0001127602-20-029014 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,981 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 76.92 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 1,286 | $212.11 | $272,773.46 |
DisclosureSEC source: 0001127602-20-029007 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,434 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 1,804 | $212.11 | $382,646.44 |
DisclosureSEC source: 0001127602-20-029007 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,720 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:18 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 2,135 | $212.11 | $452,854.85 |
DisclosureSEC source: 0001127602-20-029007 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,524 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 56.52 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 05, 2020 Filed Nov 14, 2020 02:03 UTC |
Leong JustinPresident, Asia Latin America
|
Exercise / conversionResMed Common Stock Options · Derivative | 7,740 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-029036 · form4.xml · derivative · entry 3 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: ResMed Common Stock · 7,740 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2020 Filed Nov 14, 2020 02:03 UTC |
Leong JustinPresident, Asia Latin America
|
SaleReMed Common Stock | 7,740 | $211.36 | $1,635,926.40 |
DisclosureSEC source: 0001127602-20-029036 · form4.xml · nonDerivative · entry 2 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,386 Read SEC document |
| November 05, 2020 Filed Nov 14, 2020 02:03 UTC |
Leong JustinPresident, Asia Latin America
|
Exercise / conversionReMed Common Stock | 7,740 | $57.76 | $447,062.40 |
DisclosureSEC source: 0001127602-20-029036 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 19:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,918 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-028220 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 5,918 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 19:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 5,918 | $201.14 | $1,190,363.68 |
DisclosureSEC source: 0001127602-20-028220 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $197.28 to 203.32. The price reported above reflects the weighted average sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 19:01 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 5,918 | $57.76 | $341,823.68 |
DisclosureSEC source: 0001127602-20-028220 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 01:21 UTC |
Burt CarolDirector
|
GiftResMed Common Stock | 263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028057 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Carol Burt Hilliard Trust Disclosed balance after: 13,215 F1 · kind: Gift of shares to The Nature Conservancy, a nonprofit charitable 501(c)(3) organization. Ms. Burt has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:54 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $195.00 | $467,995.68 |
DisclosureSEC source: 0001127602-20-028053 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,602 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 20:36 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $195.16 | $292,740.00 |
DisclosureSEC source: 0001127602-20-027979 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,089 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:20 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $176.72 | $441,800.00 |
DisclosureSEC source: 0001127602-20-027222 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,275 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 20:04 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,125 | $176.72 | $198,810.00 |
DisclosureSEC source: 0001127602-20-027196 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 182,313 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:08 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-026627 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,918 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:08 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 5,919 | $170.07 | $1,006,620.65 |
DisclosureSEC source: 0001127602-20-026627 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $168.72 to 171.06. The price reported above reflects the weighted average sale price. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:08 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-026627 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:46 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $172.84 | $259,260.00 |
DisclosureSEC source: 0001127602-20-026300 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,589 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:44 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $170.43 | $409,022.88 |
DisclosureSEC source: 0001127602-20-026298 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 22:35 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $175.49 | $438,725.00 |
DisclosureSEC source: 0001127602-20-025254 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,775 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:01 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,147 | $175.49 | $201,287.03 |
DisclosureSEC source: 0001127602-20-025213 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 183,438 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 21:00 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-024769 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,837 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 21:00 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 5,919 | $177.52 | $1,050,714.24 |
DisclosureSEC source: 0001127602-20-024769 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $175.44 to 181.64. The price reported above reflects the weighted average sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.